TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
One Percent Rule Checklist For Safer Forex Trading Risk 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
MENLO PARK, Calif., April 09, 2017 -- Geron Corporation (Nasdaq:GERN) will host a conference call on April 10, 2017, at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2/3 trial in myelodysplastic syndromes and the Phase 2 trial in myelofibrosis.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID number is 6116409. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast will also be available through the company’s website at www.geron.com in the Investors section under Events and at http://edge.media-server.com/m/p/w5mtfw9k. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through May 11, 2017.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
